

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.,
Petitioner,

v.

NOVARTIS PHARMA AG,
NOVARTIS TECHNOLOGY LLC,
NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owner.

Case No. Unassigned
U.S. Patent No. 9,220,631

**POWER OF ATTORNEY FOR PETITIONER
REGENERON PHARMACEUTICALS, INC.**

Pursuant to 37 C.F.R. § 42.10(b), Petitioner Regeneron Pharmaceuticals, Inc., hereby appoints the following practitioners as their attorneys to transact all business in the United States Patent & Trademark Office connected to the above-captioned *Inter Partes* Review of U.S. Patent No. 9,220,631:

LEAD COUNSEL	BACK-UP COUNSEL
<p>Elizabeth Stotland Weiswasser Reg. No. 55,721 Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 elizabeth.weiswasser@weil.com Phone: 212-310-8022 Fax: 212-310-8007</p>	<p>Anish R. Desai Reg. No. 73,760 Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 anish.desai@weil.com Phone: 212-310-8730 Fax: 212-310-8007</p>
	<p>Brian E. Ferguson Reg. No. 36,801 Weil, Gotshal & Manges LLP 2001 M Street, N.W., Suite 600 Washington, D.C. 20036 brian.ferguson@weil.com Phone: 202-682-7516 Fax: 202-857-0940</p>
<p>Service E-mail: <u>REGN.IPR.Service@weil.com</u></p>	<p>Christopher M. Pepe Reg. No. 73,851 Weil, Gotshal & Manges LLP 2001 M Street, N.W., Suite 600 Washington, D.C. 20036 christopher.pepe@weil.com Phone: 202-682-7018 Fax: 202-857-0940</p>
	<p>Natalie C. Kennedy Reg. No. 68,511 Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 natalie.kennedy@weil.com Phone: 212-310-8227 Fax: 212-310-8007</p>

LEAD COUNSEL	BACK-UP COUNSEL
	<p>Andrew P. Gesior Reg. No. 76,588 Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 andrew.gesior@weil.com Phone: 212-310-8244 Fax: 212-310-8007</p> <hr/> <p>Priyata Y. Patel Reg. No. 76,861 Weil, Gotshal & Manges LLP 2001 M Street, N.W., Suite 600 Washington, D.C. 20036 priyata.patel@weil.com Phone: 202-682-7041 Fax: 202-857-0940</p>

The undersigned has the authority to execute this document on behalf of
Petitioner Regeneron Pharmaceuticals, Inc.

Dated: July 14, 2020



Larry Coury
Vice President, Associate General Counsel
Regeneron Pharmaceuticals, Inc.